Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 30Vincristine 22Rituximab 19Etoposide 19Prednisone 18Filgrastim 16Doxorubicin 16Cytarabine 16Methotrexate 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13merphos 11Leucovorin 11blinatumomab 10N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Dexamethasone 10azathiopurine 9Specimen Handling 9Methylprednisolone 9Calcium Dobesilate 9Biopsy 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Cyclosporine 8prednylidene 7pegaspargase 7fludarabine phosphate 7deltacortene 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Burkitt Lymphoma × CX 5461 × Clear all
NCT07069699 2026-05-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

National Cancer Institute (NCI)

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡